🔥 Featured Questions
🔥 Trending:🆕 NewestTechburgerSportsMusicLifestyle & Trends
🗂️ Categories:EntertainmentBooksBeauty & SkincareFood & DrinkTech & AIRelationshipsLifestyle & TrendsMoney & FinanceSports
Is Tadej Poga?ar the greatest cyclist of all time after his 5th Tour de France win?

Poga?ar just won his 5th Tour de France title.

🏆 Leading: Not yet, he needs more time (50%)🥈 Yes, case closed (25%)🥉 No, another rider still deserves that title (25%)🌍 🇫🇷 France, 🇪🇬 Egypt, 🇭🇰 Hong Kong

Poll as Guest Infographics
Also worth a voteIs Jannik Sinner the best men's tennis player right now after defending his Wimbledon title?Does Spain's 2nd World Cup title make them the best team of this era?Who's the greatest NBA player of all time?
From around the web

Similar to hewsay's "Is Tadej Poga?ar the greatest cyclist of all time after his 5th Tour de France win?"

Quoted & linked with attribution — not a hewsay user post.
Is Tadej Pogacar on track to become one of the greatest cyclists of all time? Is Tadej Pogacar the greatest cyclist of all time? Is Tadej Pogacar the greatest cyclist of all time? Is Tadej Pogacar the greatest cyclist of all time? Vingegaard could be a stronger Grand Tour ride...
quora.com · Quora
View original
What makes Tadej Pogacar the best cyclist in the world? Pogacar is the highest ranked active cyclist, with 11 points (two Tours, one Ronde, one Liege, three Lombardia). Is Tadej Pogacar the greatest cyclist of all time? Pro riders, and especially those who can win the Tour de ...
quora.com · Quora
View original
Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?

On August 19, 2026, Moderna's shares skyrocketed as much as 177% in a single session -- the biggest one-day gain in the company's history -- after it and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, hit its primary and secondary endpoints in combination with Keytruda in a Phase 3 melanoma trial of over 1,100 patients. The move added roughly $44 billion in market value in hours and instantly vaulted Moderna past every Wall Street analyst's price target, since the stock had carried only a consensus "Hold" rating and a $52.95 average target just the day before. Short sellers, caught badly offside, are estimated to have lost around $5.5 billion in the squeeze. Is this a legitimate re-rating of a real oncology breakthrough, an overexcited bet on a speculative pipeline still years from approval, or a technically-driven overreaction fueled by short covering that could partially unwind?

🏆 Leading: It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight. (75%)🥈 It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype. (25%)🌍 🇨🇳 China
It's justified -- this was a real, data-backed breakthrough. The Phase 3 INTerpath-001 trial wasn't a rumor or an early-stage readout -- it was a randomized study of over 1,100 melanoma patients showing intismeran autogene plus Keytruda meaningfully beat Keytruda alone on both recurrence-free and distant metastasis-free survival, exactly the kind of hard clinical data biotech investors dream of. With no new safety concerns and a clear runway toward FDA submission, the market simply corrected years of undervaluing Moderna's post-pandemic pipeline overnight.
It's hype -- investors are pricing in a perfect future. A 177% single-day pop that instantly blows past every analyst's price target isn't calm repricing, it's a euphoric bet on years of trials that haven't even happened yet, since FDA approval and actual commercial revenue for intismeran autogene are still years away. This mirrors the same speculative dynamic that inflated Moderna's stock during the COVID vaccine boom, before it slowly bled out over the following years as reality caught up with the hype.

Poll as Guest Infographics
Also worth a voteModerna Stock Nearly Triples in a Day -- Cancer Breakthrough, Flu Shot Win, or Just a Short Squeeze?Moderna's cancer vaccine stock rocketed 177% then crashed 25% the next day — and RFK Jr had axed $500M in mRNA funding a year earlier. Who read this right?48% of Americans hope AI cures cancer or Alzheimer's — but only 15% trust the companies building it. Is that optimism justified?
From around the web

Similar to hewsay's "Moderna Stock Exploded 177% in One Day on a Cancer Vaccine Breakthrough -- Is This Justified Science, Pure Hype, or a Short-Squeeze Overreaction?"

Quoted & linked with attribution — not a hewsay user post.
# AI is curing cancer (Moderna's Intismeran vaccine). It doesn't seem like the connection between AI and Moderna and Merck's breakthrough with its skin cancer vaccine, Intismeran, has been made. Moderna stock (MRNA) has gone up 83% year to date on the news that the vaccine is ...
reddit.com · Reddit
View original
# I Just Bought $510K Worth of Moderna Stock. r/ModernaStock - I Just Bought $510K Worth of Moderna Stock. Moderna (MRNA) is completely undervalued right now. It's clear that short sellers are driving down the price in the short term, but in the mid-to-long term, I believe the...
reddit.com · Reddit
View original